ArticleClinical, cosmetic and investigational dermatology2025
Promotion of Random Flap Neovascularisation in Rats with Diabetes Using Botulinum Toxin Type A Through the HIF-1α/VEGF Pathway.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the effects of botulinum toxin type A (BoTA) on the neovascularisation of diabetic flaps through the factor-1alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway. Methods: A total of 60 male Wistar rats (250-300 g) were randomly divided into 4 groups. Group A consisted of normal rats receiving saline, Group B received BoTA, Group C were diabetic rats treated with saline, and Group D were diabetic rats treated with BoTA. Random-pattern dorsal skin flaps (3×9 cm) were created, and saline or BoTA was injected at proximal, mid and distal regions. Ten days later, orthotopic flap transplantation was performed. After 7 days, flap survival rate, haematoxylin-eosin (H&E) staining, and the mRNA expression of HIF-1α and VEGF were evaluated. Results: Flap survival area significantly increased in Group B compared to Group A (P < 0.05), and in Group D compared to Group C (P < 0.05). The highest neovascular density was observed in Group B (P < 0.05), while the lowest was in Group C (P < 0.05). No significant difference was found between Groups A and D. Reverse transcription polymerase chain reaction (RT-PCR) showed that HIF-1α and VEGF expression levels were highest in Group B, followed by Groups A, D, and C (P < 0.05). Conclusion: BoTA promotes flap survival and neovascularisation in diabetic rats by enhancing HIF-1α and VEGF expression. These results suggest a potential therapeutic role of BoTA in improving flap outcomes in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.